Vernal Biosciences, a leader in mRNA and LNP manufacturing, and REPROCELL Inc., Japan’s first induced pluripotent stem cell (iPSC) company, have partnered to provide mRNA services in Japan at scale for research
and clinical applications.
Under the guidance and expertise of Vernal’s Founder and CEO Dr. Christian Cobaugh, and Duncan Liew, Ph.D, SVP, Commercial Operations, training with the REPROCELL team on mRNA capabilities and processes has already begun. Considering REPROCELL is already best in class in the stem cell field, this will align with REPROCELL’s goal to bring leading-edge solutions to
market for preclinical and clinical research.
According to Dr. Cobaugh, this new relationship between the two companies is significant for drug development on a global scale, “Japan has a rich history of developing innovative and life saving medicines. However, the future of that innovation depends on a supply of high purity drug substance and product for advanced therapeutics, particularly in the mRNA medicines
field where Vernal is a leader. Through our partnership with REPROCELL, drug developers of mRNA therapeutics now have unlimited access to mRNA manufacturing and LNP formulation services. We’re excited about this partnership because it furthers our mission to democratize
access to mRNA, a life-changing technology, around the world.”
“REPROCELL is entering the mRNA and LNP market in response to the growing interest in mRNA drugs in Japan. Through this partnership with Vernal, we are pleased to offer access to our clients in Japan for mRNA therapeutic modality, in addition to our existing offerings for GMP
iPSC, MSC and MSC-products including cell-free MSC-derivatives.” said Chikafumi Yokoyama Ph.D., CEO of REPROCELL Inc.
With the launch of this partnership, REPROCELL’s customers now have access to Vernal Biosciences GMP-grade mRNA and LNP manufacturing capabilities, which helps REPROCELL do even more to provide researchers with mRNA services from bench to clinic. mRNA is also a tool in reprogramming stem cells and may be a huge partner asset to those who benefit fromREPROCELL’s many offerings.
